Premium
A clinical trial of intravenous and intracavitary bleomycin
Author(s) -
Cunningham Thomas J.,
Olson Kenneth B.,
Horton John,
Wright Ausma,
Hussain Maleka,
Davies Jack N. P.,
Harrington George
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197205)29:5<1413::aid-cncr2820290544>3.0.co;2-r
Subject(s) - bleomycin , medicine , metaplasia , lung , gastrointestinal tract , lesion , pathology , pulmonary fibrosis , fibrosis , respiratory tract , carcinoma , gastroenterology , chemotherapy , respiratory system
Bleomycin, used in two intravenous treatment schedules, induced little tumor regression in 44 patients with advanced carcinoma. Intracavitary instillation resulted in a decrease of fluid reaccumulation in 40% of patients. Bleomycin therapy was associated with toxic reactions in the skin, mucosa, or gastrointestinal tract in 50% of the patients. A severe pulmonary reaction progressing to death occurred in two patients. Cuboidal metaplasia of the alveolar cells with an intra‐alveolar exudate appeared as the primary pulmonary lesion. The principal changes in the lung were in the alveoli and might represent an early phase in the formation of pulmonary fibrosis.